Alliance Pharmaceuticals

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk


Summary of Product Characteristics last updated on the eMC: 12/08/2010
SPC Naseptin Nasal Cream

Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Naseptin Nasal Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Chlorhexidine dihydrochloride

0.1% w/w

Neomycin sulphate

0.5% w/w

Excipients: Contains 8% w/w (80mg/g) cetostearyl alcohol

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

A smooth white cream with a fatty odour.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Eradication of nasal infection with, and carriage of, Staphylococci.


Go to top of the page
4.2 Posology and method of administration

For nasal application only.

A small amount of Naseptin is placed on the little finger and applied to the inside of each nostril.

For prophylaxis: Naseptin is applied as above, twice daily, to prevent patients from becoming carriers and to inhibit the dispersion of Staphylococci.

For eradication of infection: Naseptin is applied four times daily for 10 days to eliminate organisms from the nares.

Children and elderly patients: There are no special dosage recommendations for either children or elderly patients.


Go to top of the page
4.3 Contraindications

Patients who have previously shown a hypersensitivity reaction to neomycin or chlorhexidine, although such reactions are extremely rare.


Go to top of the page
4.4 Special warnings and precautions for use

For nasal application only. Keep out of the eyes and ears.

Naseptin contains Arachis oil (peanut oil) and should not be taken/applied by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to Soya, patients with Soya allergy should also avoid Naseptin.

Irritative skin reactions can occasionally occur. Prolonged use of neomycin can lead to skin sensitisation, ototoxicity and nephrotoxicity.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Chlorhexidine and neomycin cannot be detected in the blood following application of Naseptin and its use is unlikely to have any effect on the foetus or on breast feeding.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Irritative skin reactions can occasionally occur.

Topical application of neomycin preparations can lead to skin sensitisation in a small number of patients. Prolonged use of neomycin can lead to ototoxicity and nephrotoxicity. Therefore, use with caution in children, elderly patients and patients with impaired hearing.

Anaphylaxis to chlorhexidine has been reported rarely.


Go to top of the page
4.9 Overdose

Accidental ingestion of the contents of a Naseptin tube is unlikely to have any adverse effects on the patient.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Chlorhexidine is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is inactive against bacterial spores except at elevated temperatures.

Neomycin is a rapidly bactericidal aminoglycoside antibiotic effective against Gram positive organisms including staphylococci and a wide range of Gram negative organisms. Strains of Pseudomonas aeruginosa are resistant to neomycin, as are fungi and viruses.


Go to top of the page
5.2 Pharmacokinetic properties

Because of its cationic nature, chlorhexidine binds strongly to the skin, mucosa and other tissues and is thus very poorly absorbed. No detectable blood levels have been found in man following oral use and percutaneous absorption, if it occurs at all, is insignificant.

Neomycin is either not absorbed or is absorbed only minimally through intact skin. Any neomycin which is absorbed will be rapidly excreted by the kidneys in an unchanged state.


Go to top of the page
5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to those already included in other sections of the Summary of Product Characteristics.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Arachis oil, cetostearyl alcohol, cetostearyl alcohol/ethylene oxide condensate, purified water.


Go to top of the page
6.2 Incompatibilities

Hypochlorite bleaches may cause brown stains to develop in fabrics which have previously been in contact with preparations containing chlorhexidine.

Chlorhexidine is incompatible with soap and other anionic agents.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

Store below 30°C.


Go to top of the page
6.5 Nature and contents of container

Collapsible, internally lacquered aluminium tubes of 15g with white food-grade polypropylene screw caps.


Go to top of the page
6.6 Special precautions for disposal and other handling

For nasal application only.


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Alliance Pharmaceuticals Ltd

Avonbridge House

Bath Road

Chippenham

Wiltshire

SN15 2BB


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL16853/0024


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

August 1999


Go to top of the page
10. DATE OF REVISION OF THE TEXT

30th June 2010


Go to top of the page
Legal Status

POM

Alliance, Alliance Pharmaceuticals and associated devices are registered Trademarks of Alliance Pharmaceuticals Ltd.



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/2503/SPC/


Active Ingredients/Generics

 
   neomycin sulphate
   chlorhexidine dihydrochloride